BURVAQUIN Injectable Solution is an FDA-approved antibiotic specifically designed for the treatment of lower respiratory tract infections in horses. Let’s delve into the details:
-
- Indication and Target Pathogen:
- BURVAQUIN is indicated for treating infections caused by Streptococcus equi subspecies zooepidemicus (S. zooepidemicus).
- S. zooepidemicus is a common pathogen associated with equine respiratory infections.
- Mechanism of Action:
- BURVAQUIN contains ceftiofur crystalline free acid, a broad-spectrum cephalosporin antibiotic.
- It acts by inhibiting bacterial cell wall synthesis, effectively targeting both gram-positive and gram-negative bacteria.
- Sustained-Release Advantage:
- BURVAQUIN is the first and only sustained-release antibiotic approved for horses.
- With just two treatments, it provides a full 10-day course of therapy.
- This dosing schedule enhances compliance and convenience for horse owners and veterinarians.
- Effective Relief and Rapid Action:
- Horses respond rapidly to BURVAQUIN, experiencing relief within 5–10 minutes.
- Most achieve relief from colic spasms within 30 minutes.
- Fewer administrations reduce the risk of missed doses compared to daily treatments.
- Safety Considerations:
- Avoid BURVAQUIN use in impaction colics associated with ileus or in horses with glaucoma.
- Transient elevated heart rate is a common side effect post-injection.
- Overall Benefit:
- BURVAQUIN effectively manages respiratory infections, allowing horses to recover comfortably.
- Indication and Target Pathogen:
Reviews
There are no reviews yet.